Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927692 · ClinicalTrials.gov registry record
Therapeutic Plasma Exchange in MG
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 11
- Enrollment target
NCT01927692: Completed study, sponsored by Duke University.
NCT01927692 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01927692 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The primary objective of the study is to longitudinally profile immunoglobulin levels and autoantibody levels in subjects with myasthenia gravis (MG) who receive therapeutic plasma exchange (TPE).
Primary Outcome
Immunoglobulin and IgG subtype levels, AChR autoantibody levels, IgG/autoantibody ratio will be listed, summarized and plotted graphically by visit.
Interventions
- OTHER Skin biopsy
- OTHER Single Fiber Electromyography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-10 |
What the finished NCT01927692 record still lists
NCT01927692 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Skin biopsy is the first listed.
NCT01927692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01927692 about?
NCT01927692 is a clinical study titled "Therapeutic Plasma Exchange in MG". The primary objective of the study is to longitudinally profile immunoglobulin levels and autoantibody levels in subjects with myasthenia gravis (MG) who receive therapeutic plasma exchange (TPE).
What is the current status of trial NCT01927692?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2013-07. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01927692?
The interventions under investigation include: Skin biopsy (OTHER), Single Fiber Electromyography (OTHER).
Who is sponsoring clinical trial NCT01927692?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia